Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORX142 in healthy adults and sleep-deprived subjects
NCT07082829Phase 1Recruiting
- Sponsor
- Centessa Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ORX142 in Excessive Daytime Sleepiness (EDS) (5 arms), sponsored by Centessa Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 13 days. Started Jun 2025; status: recruiting.
02
Drugs
ORX142
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on NCT07082829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082829.